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Complexity of antiretroviral treatment (ART) is a reason for non-adherence and may impact treatment outcome.The association
between daily dosing and pill burden and chance of virological success (VS) of first ART has been rarely assessed. 3,674 naı ¨ve
patients who started treatment after January 2000 were identified from the ICoNA cohort. Number of daily doses and pills were
estimated on the basis of the drugs used to rank first ARTcomplexity: 12 daily pills once a day (low-pills QD [lpQD]); 36 daily
pills QD (high-pills QD [hpQD]); 25 daily pills BID (low-pills BID [lpBID]);  6 daily pills BID (high-pills BID [hpBID]). VS was the
date of first HIV RNA B50 cp/ml. Follow-up was censored at the date of VS or last available HIV RNA. Kaplan-Meier curves
estimated probability of achieving VS according to ART complexity. Univariable and multivariable Cox regression stratified by
clinical site was used to identify variables associated with VS. ITTprinciple was applied, using competing risk approach for death.
Population: male 75%; median age 37 y (IQR, 3244); HIV transmission heterosexual 43%, homosexual 33%, drug use 16%;
Italian origin 86%; CDC group C 17%; median pre-ART CD4 and log HIV-RNA were 271/mm
3 (range, 01672) and 4.84 cp/ml
(1.706.38), respectively. Regimens were started in ‘00‘02 24%,‘03‘05 17%,‘06‘08 17%,‘09‘12 42% and based on NNRTI in
40%, PI/r 43%, PI 8%, other ART 10%. Frequencies in complexity ranks were: 19% lpQD, 23% hpQD, 32% lpBID, 26% hpBID. VS
was achieved by 85% of patients with an overall median time to VS of 5.6 months (95% CI: 5.45.8). Median months to VS were
shorter with decreasing complexity: hpBID 6.5; lpBID 6.0; hpQD 5.3, lpQD 4.5. Kaplan-Meier curves are shown (Figure).
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1After stratifying for clinical site and adjusting for age, gender, origin, transmission route, CDC group C, HCV/HBV infection, years
of HIV, pre-cART CD4 and HIV-RNA, type of regimen a significantly reduced likelihood of achieving VS was found for ART
complexity (hpQD: HR 0.76 95% CI 600.96; lpBID: 0.74, 0.590.94) when compared with lpQD.The chance of VS was higher in
people starting ART more recently (RH 1.28 [95% CI 1.091.51] for ‘03‘05; RH 1.64 [1.272.10] for ‘09‘12; vs. ‘00‘02) and
was lower in people with previous AIDS (RH 0.85 [0.730.98]). Once-a-day dosing of ART, especially when combined with low
daily pill burden, seems to be one of main factors contributing to the higher rate of success of ART in recent years.
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